CD8A and non-small cell lung carcinoma: PD-L1-/CD8 low NSCLC patients after CCRT had the longest overall survival, while PD-L1+/CD8 low patients with locally advanced NSCLC after CCRT had the shortest overall survival (Gennen et al., 2020).